Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Mantle Cell Lymphoma

Mantle Cell Lymphoma

Part of Non-Hodgkin's Lymphoma

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Mantle Cell Lymphoma

148 trials tracked for Mantle Cell Lymphoma: 10 in phase 3 or 4 and 5 with published results. The most-cited published study has 473 citations.

148Trials tracked
10Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 118 Phase 1 12 Other / NA 8
  1. Phase 3 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed · 473 cited
  2. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed · 228 cited
  3. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 115 cited
  4. Phase 3 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) Completed · 53 cited
  5. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 9 cited
  6. Phase 4 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Completed
Show 44 more trials
  1. Phase 3 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed
  2. Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed
  3. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  4. Phase 3 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed
  5. Phase 2 A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma Completed
  6. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  7. Phase 2 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Completed
  8. Phase 2 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Completed
  9. Phase 2 Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma Completed
  10. Phase 2 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed
  11. Phase 2 A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) Completed
  12. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  13. Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Completed
  14. Phase 2 A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Completed
  15. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  16. Phase 2 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma Completed
  17. Phase 2 Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma Completed
  18. Phase 2 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Completed
  19. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  20. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  21. Phase 2 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Completed
  22. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  23. Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Completed
  24. Phase 2 VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma Completed
  25. Phase 2 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  26. Phase 2 Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Completed
  27. Phase 2 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed
  28. Phase 2 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Completed
  29. Phase 2 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Completed
  30. Phase 2 A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial Completed
  31. Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) Completed
  32. Phase 2 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed
  33. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  34. Phase 2 Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma Completed
  35. Phase 2 Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy Completed
  36. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  37. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  38. Phase 2 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Completed
  39. Phase 2 Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell Completed
  40. Phase 2 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed
  41. Phase 2 Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma Completed
  42. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  43. Phase 2 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Completed
  44. Phase 2 EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Completed

Showing the 50 most-cited and recently-updated of 148 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Mantle Cell Lymphoma: what the trials found

Ibrutinib has demonstrated significant improvements in progression-free survival (PFS) and complete response rates in several trials. Specifically, one trial showed a PFS of 15.6 vs 6.2 months (p < 0.0001) 4, while another reported a PFS of 31.9 vs 22.1 months (p = 0.0024) and a complete response rate of 53.7% vs 32.3% (p = 0.0004) 7.

Bendamustine is associated with high overall response rates, ranging from 88.5% to 100% across different study cohorts [5, 12]. One trial showed a significant improvement in PFS with bendamustine (52.9 vs 80.6; p = 0.011) 5, while another reported high overall response rates of 93% to 100% 12.

Rituximab at 375 mg/m^2 showed statistically significant improvements in progression-free survival (437.0 vs 751.0; p < 0.001), time to progression (490.0 vs 929.0; p < 0.001), and time to next anti-lymphoma treatment (756.0 vs 1353.0; p < 0.001) 9.

Fludarabine was associated with a disease-free survival of 70.6% (p = 0.002) and an overall survival of 73.3% in one study 20. Other trials evaluating fludarabine or its combinations showed high overall response rates of up to 97% 11.

Recent results — preliminary, needs further review

  • Lenalidomide demonstrated progression-free survival at 18 weeks ranging from 85.7% to 100% and a 2-year response rate between 66.7% and 100% 1.
  • BeEAM showed an overall survival of 92.3% and 88.6% in a small cohort 14.
  • G-CSF was associated with a 5-year progression-free survival rate of 57.1% and a 5-year overall survival rate of 79.7% 15.

For the clinician treating this condition

  • Ibrutinib is supported by evidence showing significant improvements in both progression-free survival and complete response rates compared to standard controls.
  • Bendamustine consistently achieves high overall response rates (up to 100%) across multiple trials.
  • Rituximab at 375 mg/m^2 significantly extends progression-free survival and time to next anti-lymphoma treatment.
  • Fludarabine is associated with favorable disease-free survival and high overall response rates in established cohorts.

AI synthesis of 10 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
Hematology Meta-analysis
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Oct 1, 2026
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma
Oncology Meta-analysis
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma Trial Shows Brexucabtagene Autoleucel Provides Durable Benefit for Blood Cancers
This meta-analysis of 31 cohorts evaluates brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma and B-cell acute lympho…
Brexucabtagene autoleucel shows high response rates and durable benefits for adults with specific types of relapsed or refractory blood canc…
Oct 1, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026

Research across Non-Hodgkin's Lymphoma

Related studies from across the Non-Hodgkin's Lymphoma family.

Diffuse large B-cell lymphoma of the uterus presents with varied symptoms and 11q gain
Rheumatology Sys. Review
Diffuse large B-cell lymphoma of the uterus presents with varied symptoms and 11q gain Review Identifies Common Symptoms and Treatments for Uterine Lymphoma
This case report and literature review examines uterine lymphoma, specifically focusing on a case of DLBCL with 11q23.3/11q24.3 gain. The re…
New data highlights common symptoms like vaginal bleeding and pelvic masses in patients with uterine lymphoma to help guide clinical care.
Frontiers Nov 6, 2026
Rituximab monotherapy prolongs time to new treatment but not overall survival in low-tumor-burden follicular lymphoma
Hematology Meta-analysis
Rituximab monotherapy prolongs time to new treatment but not overall survival in low-tumor-burden follicular lymphoma Rituximab monotherapy delays new treatment for advanced follicular lymphoma
This meta-analysis of 1590 patients evaluated rituximab monotherapy versus watchful waiting in advanced-stage low-tumor-burden follicular ly…
Rituximab may help patients with advanced follicular lymphoma stay on their current treatment longer, though it did not change overall survi…
Nov 4, 2026
Baseline anti-HBc positivity does not impact 3-year PFS or OS in HBsAg-negative DLBCL
Gastroenterology RCT
Baseline anti-HBc positivity does not impact 3-year PFS or OS in HBsAg-negative DLBCL Hepatitis B history does not impact lymphoma treatment outcomes
This supplementary analysis of a Phase II/III trial involved 405 patients with HBsAg-negative diffuse large B-cell lymphoma treated with rit…
Patients with a history of hepatitis B and certain types of lymphoma saw the same survival rates as those without it.
Nov 2, 2026
Teclistamab and glofitamab carry higher non-relapse mortality signals than mosunetuzumab in BsAb meta-analysis
Oncology Meta-analysis
Teclistamab and glofitamab carry higher non-relapse mortality signals than mosunetuzumab in BsAb meta-analysis New data reveals safety risks for certain lymphoma and myeloma drugs
This meta-analysis combined a systematic review and meta-analysis with FAERS pharmacovigilance data to estimate non-relapse mortality (NRM) …
New data highlights different safety risks and side effects for three specific drugs used to treat certain types of blood cancers.
Nov 1, 2026
Glofitamab plus selinexor maintenance yields sustained CR in refractory DLBCL case
Anesthesiology & Pain Medicine Sys. Review
Glofitamab plus selinexor maintenance yields sustained CR in refractory DLBCL case New treatment strategy shows promise for hard to treat lymphoma
This case report and literature review describes a 70-year-old man with primary refractory DLBCL harboring TP53 and CD58 mutations who achie…
A new treatment plan using glofitamab and selinexor helped a 70-year-old man with a very aggressive form of lymphoma achieve a lasting respo…
Frontiers Oct 30, 2026
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
Drug Pipeline Meta-analysis
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Frontiers Oct 21, 2026
Allo-HSCT after CAR-T yields sustained remission in DLBCL patient with secondary MDS
Diabetes & Endocrinology Sys. Review
Allo-HSCT after CAR-T yields sustained remission in DLBCL patient with secondary MDS CAR-T and transplant may lead to secondary leukemia
This case report and literature review describes a single patient with primary splenic DLBCL who developed secondary myelodysplastic syndrom…
A patient developed a secondary blood cancer after CAR-T therapy and transplant, but a later transplant brought remission.
Frontiers Aug 27, 2026
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients
Oncology RCT
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients Nursing Program Reduces Fall Risk for Lymphoma Patients
This randomized controlled trial of 210 older adults with non-Hodgkin's lymphoma found that a multifaceted preventive nursing program signif…
A specialized nursing program significantly reduced falls and improved mobility for older adults undergoing chemotherapy for lymphoma.
Jul 20, 2026
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Oncology Meta-analysis
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
Jul 4, 2026
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
Oncology Meta-analysis
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Jul 3, 2026
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Nutrition & Obesity Medicine Meta-analysis
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Frontiers Jun 24, 2026
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
Allergy & Immunology Meta-analysis
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Frontiers Jun 23, 2026